Corporate News
Adma Biologics (ADMA)
- Price movement – The Adma Biologics share closed 1.96 % lower at USD 11.01 during the 24‑hour period ending 10:22 AM Central Europe on Thursday, 22 April 2026.
- Market data – Current trading price: USD 11.01.
- Supply – 224.4 million shares outstanding.
- Market capitalization – USD 2.5 billion.
- Recent trading volume – USD 22.1 million of shares were traded in the last 24 hours.
- Month‑to‑date performance – Since the end of the previous month, the stock has risen 12.23 %.
- Technical indicators –
- 200‑day simple moving average: USD 11.20.
- 52‑week high: USD 20.46 (12 December 2025).
- 52‑week low: USD 7.21 (26 March 2026).
Related Stock Performance (Last 24 Hours)
| Symbol | Current Price | Change | Market Capitalisation | P/E Ratio |
|---|---|---|---|---|
| HTGC (Hercules Capital) | USD 16.27 | –0.06 % | USD 3.0 billion | 8.09 |
| CBZ (Cbiz) | USD 54.85 | –0.07 % | USD 3.0 billion | 23.87 |
| DYN (Dyne Therapeutics) | USD 16.07 | –1.23 % | USD 3.0 billion | – |
| CELC (Celcuity) | USD 61.56 | +2.60 % | USD 3.0 billion | – |
| RCUS (Arcus Biosciences) | USD 19.10 | –19.58 % | USD 3.0 billion | – |
Arcus Biosciences (RCUS) – Public Offering Update
- Offering details – Arcus announced a public offering of its common stock, including a 30‑day underwriter option for additional shares.
- Closing date – The offering is scheduled to close on 23 October 2026.
- Use of proceeds – Net proceeds will support research and development for cancer and immune‑disease programs, and for general corporate purposes.
- Cash position – As of the end of September 2026, the company held approximately USD 694 million in cash, cash equivalents, and marketable securities.
- Dilution risk – The company disclosed that underwriters have an option to purchase up to additional shares at the offering price and outlined potential dilution and risk factors related to future equity issuances.
Company Overview
- Name – ADMA Biologics, Inc.
- Location – Ramsey, United States.
- Business focus – Development and commercialization of human plasma and plasma‑derived therapeutics for patients with compromised immunity.
